Valvular Heart Disease Associated with Fenfluramine–Phentermine
- 28 August 1997
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 337 (9) , 581-588
- https://doi.org/10.1056/nejm199708283370901
Abstract
Fenfluramine and phentermine have been individually approved as anorectic agents by the Food and Drug Administration (FDA). When used in combination the drugs may be just as effective as either drug alone, with the added advantages of the need for lower doses of each agent and perhaps fewer side effects. Although the combination has not been approved by the FDA, in 1996 the total number of prescriptions in the United States for fenfluramine and phentermine exceeded 18 million.Keywords
This publication has 12 references indexed in Scilit:
- Anorexic Agents Aminorex, Fenfluramine, and Dexfenfluramine Inhibit Potassium Current in Rat Pulmonary Vascular Smooth Muscle and Cause Pulmonary VasoconstrictionCirculation, 1996
- Appetite-Suppressant Drugs and the Risk of Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Carcinoid Heart DiseaseCirculation, 1995
- Primary pulmonary hypertension and fenfluramine use.Heart, 1993
- Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.Circulation, 1993
- Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic CorrelationsAnnals of Internal Medicine, 1992
- Irreversible pulmonary hypertension after treatment with fenfluramine.BMJ, 1986
- Doppler Echocardiography: Theory, Instrumentation, Technique, and ApplicationMayo Clinic Proceedings, 1985
- A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combinationArchives of internal medicine (1960), 1984
- Pharmacokinetics of absorption, distribution and elimination of fenfluramine and its main metabolite in manJournal of Pharmacy and Pharmacology, 1972